Janus Henderson Group PLC Savara Inc Transaction History

Janus Henderson Group PLC

  • $194 Billion
  • Q2 2025

A detailed history of Janus Henderson Group PLC transactions in Savara Inc stock. As of the latest transaction made, Janus Henderson Group PLC holds 42,400 shares of SVRA stock, worth $172,992. This represents 0.0% of its overall portfolio holdings.

Number of Shares
42,400
Previous 42,400 -0.0%
Holding current value
$172,992
Previous $117,000 17.95%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025
SELL
$2.94 - $4.07 $597,996 - $827,838
-203,400 Reduced 82.75%
42,400 $130,000
Q3 2024

Nov 14, 2024
SELL
$3.96 - $5.07 $8.04 Million - $10.3 Million
-2,030,660 Reduced 89.2%
245,800 $1.04 Million
Q2 2024

Aug 14, 2024
SELL
$3.66 - $5.34 $1.05 Million - $1.53 Million
-287,160 Reduced 11.2%
2,276,460 $9.17 Million
Q1 2024

May 15, 2024
BUY
$4.19 - $5.59 $3.13 Million - $4.17 Million
746,407 Added 41.07%
2,563,620 $12.8 Million
Q4 2023

Feb 14, 2024
SELL
$3.18 - $4.9 $582,859 - $898,116
-183,289 Reduced 9.16%
1,817,213 $8.54 Million
Q3 2023

Nov 14, 2023
BUY
$2.97 - $3.88 $5.94 Million - $7.76 Million
2,000,502 New
2,000,502 $7.56 Million
Q4 2021

Feb 14, 2022
SELL
$1.04 - $1.34 $2.12 Million - $2.73 Million
-2,034,586 Closed
0 $0
Q2 2021

Aug 16, 2021
SELL
$1.51 - $2.29 $425,181 - $644,811
-281,577 Reduced 12.16%
2,034,586 $3.47 Million
Q1 2021

May 17, 2021
BUY
$1.17 - $2.33 $2.71 Million - $5.4 Million
2,316,163 New
2,316,163 $4.85 Million

Others Institutions Holding SVRA

# of Institutions
126
Shares Held
167M
Call Options Held
38.7K
Put Options Held
0
View Full List

About Savara Inc

SVRA Quotes by TradingView
  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $465M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email